JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

Nejvíce citované: 3391325

1 citací v PubMed Filtry

Nejvíce citovaný článek - PubMed ID 3391325

The effect of postfusion cell density on establishment of hybridomas

Folia biologica. 1988 ; 34 (1) : 18-22.

Folia Biol (Praha)
ISSN 0015-5500
Zdroj

Článek

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias

Hanes, Jozef
Autor Hanes, Jozef From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Kovac, Andrej
Autor Kovac, Andrej From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Kvartsberg, Hlin
Autor Kvartsberg, Hlin From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Kontsekova, Eva
Autor Kontsekova, Eva From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Fialova, Lubica
Autor Fialova, Lubica From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Katina, Stanislav
Autor Katina, Stanislav ORCID From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Kovacech, Branislav
Autor Kovacech, Branislav From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Stevens, Eva
Autor Stevens, Eva From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Hort, Jakub
Autor Hort, Jakub From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Vyhnalek, Martin
Autor Vyhnalek, Martin From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands

Neurology. 2020 Dec 01 ; 95 (22) : e3026-e3035. [epub] 20200924

ISSN 1526-632X | 0028-3878
Zdroj

OBJECTIVE: To investigate whether tau phosphorylated at Thr217 (p-tau T217) assay in CSF can distinguish patients with Alzheimer disease (AD) from patients with other dementias and healthy controls. METHODS: We developed and validated a novel Simoa immunoassay to detect p-tau T217 in CSF. There was a total of 190 participants from 3 cohorts with AD (n = 77) and other neurodegenerative diseases (n = 69) as well as healthy participants (n = 44). RESULTS: The p-tau T217 assay (cutoff 242 pg/mL) identified patients with AD with accuracy of 90%, with 78% positive predictive value (PPV), 97% negative predictive value (NPV), 93% sensitivity, and 88% specificity, compared favorably with p-tau T181 ELISA (52 pg/mL), showing 78% accuracy, 58% PPV, 98% NPV, 71% specificity, and 97% sensitivity. The assay distinguished patients with AD from age-matched healthy controls (cutoff 163 pg/mL, 98% sensitivity, 93% specificity), similarly to p-tau T181 ELISA (cutoff 60 pg/mL, 96% sensitivity, 86% specificity). In patients with AD, we found a strong correlation between p-tau T217 and p-tau T181, total tau and β-amyloid 40, but not β-amyloid 42. CONCLUSIONS: This study demonstrates that p-tau T217 displayed better diagnostic accuracy than p-tau T181. The data suggest that the new p-tau T217 assay has potential as an AD diagnostic test in clinical evaluation. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that a CSF immunoassay for p-tau T217 distinguishes patients with AD from patients with other dementias and healthy controls.

* Zobrazit nápovědu

The effect of postfusion cell density on establishment of hybridomas

Upřesnit dle MeSH